2018年中国三级医院抗菌药物管理: 全国性横断面网络调查研究

doi:10.5246/jcps.2021.12.086

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (12): 994-1007.DOI: 10.5246/jcps.2021.12.086

• 【药事管理与临床药学专栏】 • 上一篇下一篇

2018年中国三级医院抗菌药物管理: 全国性横断面网络调查研究

周越¹^,^#, 海沙尔江·吾守尔¹^,²^,^#, 张翕¹, 冯佳佳³, 林丽开³, 郑波⁴, 管晓东¹^,², 史录文¹^,²^,^*()

1. 北京大学药学院药事管理与临床药学系, 北京 100191
2. 北京大学医药管理研究中心, 北京 100191
3. 武汉大学医院管理研究所, 湖北武汉 430071
4. 北京大学第一医院临床药理研究所, 北京 100034

收稿日期:2021-05-18 修回日期:2021-06-05 接受日期:2021-06-23 出版日期:2021-12-24 发布日期:2021-12-20
通讯作者: 史录文
作者简介:
+ Tel./Fax: +86-10-82805019, E-mail: shilu@bjum.edu.cn
基金资助:
China Medical Board (Grant No. 17-270) and National Natural Science Foundation of China (Grant No. 81861138048 and 81973294).

Antimicrobial stewardship program in China’s tertiary hospitals in 2018: a nationwide cross-sectional online survey

Yue Zhou¹^,^#, Haishaerjiang Wushouer¹^,²^,^#, Xi Zhang¹, Jiajia Feng³, Likai Lin³, Bo Zheng⁴, Xiaodong Guan¹^,², Luwen Shi¹^,²^,^*()

1 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2 International Research Center for Medicinal Administration (IRCMA), Peking University, Beijing 100191, China
3 Institute of Hospital Administration, Wuhan University, Wuhan 430071, China
4 Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China

Received:2021-05-18 Revised:2021-06-05 Accepted:2021-06-23 Online:2021-12-24 Published:2021-12-20
Contact: Luwen Shi
About author:
# Yue Zhou and Haishaerjiang Wushouer contributed equally to this work.

摘要/Abstract

摘要：

本研究旨在评估中国三级医院抗菌药物管理(AMS)的发展情况, 以发现管理过程中存在的挑战并为相关政策的制定提供参考与基准。本研究是一项面向全国细菌耐药监测网(CARSS)入网三级医院的横断面问卷调查。调查问卷包括5个部分, 分别是AMS组织建设情况、技术支撑体系建立情况、抗菌药物临床应用管理情况、抗菌药物临床应用监督工作情况和AMS培训宣传情况。2018年, 所有入网CARSS的1044家三级医院中, 有140(13.4%)家医院参加了本研究。样本医院中, 139(99.3%)家医院建立了AMS; 115(82.1%)家医院的AMS结果负责人是医院院长, 83(59.3%)家医院的AMS结果负责科室是医务部门; 139(99.3%)家医院采用了抗菌药物分级管理; 感染性疾病科、感染控制部门和微生物检验科分别已在122(87.1%)、139(99.3%)和140(100%)家医院设立; 临床路径和医院个体化感染性疾病指南分别在124(85.6%)家和47(33.6%)家医院开展实施; 139(99.3%)家、138(98.6%)家和134(95.7%)家医院分别开展了门诊处方审核、住院处方审核和预防性使用抗菌药物处方审核的工作; 136(97.1%)家医院参加了全国抗菌药物临床应用监测网; 139(99.3%)家医院建立了碳青霉烯和替加环素专档管理; 140(100%)家和126(90.0%)家医院分别以不同的方式和频率对医务人员和公众开展科普教育。中国三级医院的AMS主要由医院院长领导, 涉及多个学科和行政部门之间的合作。相关部门应进一步促进和加强个体化指南的制定并建立过程与结果并重的评价体系。

关键词: 抗菌药物管理, 细菌耐药, 三级医院, 中国, 横断面网络调查

Abstract:

In the present study, we aimed to assess the development of the antimicrobial stewardship (AMS) program in China’s tertiary hospitals to identify the potential challenges for the AMS program and provide references and benchmarks for strategic policymaking. A nationwide cross-sectional study was conducted online by sending questionnaires to tertiary hospitals under China Antimicrobial Resistance Surveillance System (CARSS). The questionnaire included 5 sections regarding structure, technical support, antimicrobial use management, antimicrobial use surveillance, and education. Descriptive statistics were used for data analysis. Of the 1044 tertiary hospitals under CARSS, 13.4% (140) hospitals participated in the study. Among them, 99.3% (139/140) set up the AMS program. The hospital president (82.1%, 115/140) and medical service department (59.3%, 83/140) were responsible for AMS outcomes in most hospitals. Structured antimicrobial formulary restriction management was adopted by 99.3% (139/140) hospitals. Infectious disease department, infection control department, and microbiological laboratories were established in 87.1% (122/140), 99.3% (139/140) and 100% (140/140) hospitals, respectively. Up to 85.6% (124/140) hospitals applied clinical pathways, and 33.6% (47/140) hospitals implemented hospital-specific guidelines for infectious diseases. Outpatient prescription auditing, inpatient prescription auditing, and prophylactic antimicrobial prescription auditing of aseptic operation were performed in 99.3% (139/140), 98.6% (138/140) and 95.7% (134/140) hospitals, respectively. Up to 97.1% (136/140) hospitals participated in antimicrobial use surveillance network, and 99.3% (139/140) hospitals established the specialized management of carbapenem and tigecycline. Staff education and public education were provided with various ways and frequencies in 100% (140/140) and 90.0% (126/140) hospitals, respectively. AMS programs in China’s tertiary hospitals were primarily headed by hospital presidents and involved collaboration among various disciplines and administrative departments. More efforts should be put to further promote and strengthen the development of hospital-specific guidelines and the establishment of a progress and outcome evaluation system.

Key words: Antimicrobial stewardship, Antimicrobial resistance, Tertiary hospitals, China, Cross-sectional online survey

Supporting:

周越, 海沙尔江·吾守尔, 张翕, 冯佳佳, 林丽开, 郑波, 管晓东, 史录文. 2018年中国三级医院抗菌药物管理: 全国性横断面网络调查研究[J]. 中国药学(英文版), 2021, 30(12): 994-1007.

Yue Zhou, Haishaerjiang Wushouer, Xi Zhang, Jiajia Feng, Likai Lin, Bo Zheng, Xiaodong Guan, Luwen Shi. Antimicrobial stewardship program in China’s tertiary hospitals in 2018: a nationwide cross-sectional online survey[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(12): 994-1007.

图/表 6

Figure 1. The distribution of sample hospitals.

Table 1. Structure of AMS program.

Table 2. Technical support of AMS program.

Table 3. Antimicrobial use management of AMS program.

Table 4. Antimicrobial use surveillance of AMS program.

Table 5. Education of AMS program.

参考文献 42

[1]	Spellberg, B.; Bartlett, J.G.; Gilbert, D.N. The future of antibiotics and resistance. N. Engl. J. Med. 2013, 368, 299–302.
[2]	World Health Organization. Antimicrobial resistance: global report on surveillance 2014. This article can be found online at https://www.who.int/drugresistance/documents/surveillancereport/en/.
[3]	AMR Review. Tackling a crisis for the health and wealth of nations. This article can be found online at https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the% 20health%20and%20wealth%20of%20nations_1.pdf.
[4]	Schuts, E.C.; Hulscher, M.E.J.L.; Mouton, J.W.; Verduin, C.M.; Stuart, J.W.T.C.; Overdiek, H.W.P.M.; van der Linden, P.D.; Natsch, S.; Hertogh, C.M.P.M.; Wolfs, T.F.W.; Schouten, J.A.; Kullberg, B.J.; Prins, J.M. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect. Dis. 2016, 16, 847–856.
[5]	Davey, P.; Marwick, C.A.; Scott, C.L.; Charani, E.; McNeil, K.; Brown, E.; Gould M.; Ramsay, C.R.; Michie, S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane. Database. Syst. Rev. 2017. This article can be found online at http://doi.wiley.com/10.1002/14651858.CD003543.pub4.
[6]	Barlam, T.F.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.; Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; Hamilton, C.W.; Jenkins, T.C.; Lipsett, P.A.; Malani, P.N.; May, L.S.; Moran, G.J.; Neuhauser, M.M.; Newland, J.G.; Ohl, C.A.; Samore, M.H.; Seo, S.K.; Trivedi, K.K. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin. Infect. Dis. 2016, 62, e51–e77.
[7]	Society for Healthcare Epidemiology of America, America, I.D.S.O.; Society, P.I.D. Policy statement on antimicrobial stewardship by the society for healthcare epidemiology of America (SHEA), the infectious diseases society of America (IDSA), and the pediatric infectious diseases society (PIDS). Infect. Control. Hosp. Epidemiol. 2012, 33, 322–327.
[8]	Pollack, L.A.; Srinivasan, A. Core elements of hospital antibiotic stewardship programs from the centers for disease control and prevention. Clin. Infect. Dis. 2014, 59, S97–S100.
[9]	Pollack, L.A.; Plachouras, D.; Gruhler, H.; Sinkowitz-Cochran R. Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) Summary the modified Delphi process for common structure and process indicators for hospital antimicrobial stewardship programs. 2015. This article can be found online at https://www.cdc.gov/drugresistance/pdf/summary_of_tatfar_recommendation_1.pdf.
[10]	Xiao, Y.H. Antimicrobial stewardship in China: systems, actions and future strategies. Clin. Infect. Dis. 2018, 67, S135–S141.
[11]	Guiding Principles of Clinical Application of Antibiotics. 2015. This article can be found online at http://www.gov.cn/xinwen/2015-08/27/content_2920799.htm.
[12]	National Action Plan to Contain Antimicrobial Resistance (2016-2020). 2016. This article can be found online at http://www.gov.cn/xinwen/2016-08/25/content_5102348.htm.
[13]	Regulations for Antimicrobials Clinical Use. 2012. This article can be found online at http://www.gov.cn/flfg/2012-05/08/content_2132174.htm.
[14]	Graber, C.J.; Jones, M.M.; Chou, A.F.; Zhang, Y.; Goetz, M.B.; Madaras-Kelly, K.; Samore, M.H.; Glassman, P.A. Association of inpatient antimicrobial utilization measures with antimicrobial stewardship activities and facility characteristics of veterans affairs medical centers. J. Hosp. Med. 2017, 12, 301–309.
[15]	Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use-Guidance-NICE. This article can be found online at https://www.nice.org.uk/ guidance/ng15.
[16]	CARSS. This article can be found online at http://www.carss.cn/.
[17]	National Health and Family Planning Commission of People’s Republic of China. China Health Statistics Yearbook. Beijing: Peking Union Medical College Press; 2019.
[18]	Kamel, C.; McGahan, L.; Mierzwinski-Urban, M.; Embil, J. Preoperative Skin Antiseptic Preparations and Application Techniques for Preventing Surgical Site Infections: A Systematic Review of the Clinical Evidence and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2011. This article can be found online at http://www.ncbi.nlm.nih.gov/books/NBK174549/.
[19]	Notification on further strengthening the management of antimicrobial use and antimicrobial resistance confinement. This article can be found online at http://www.nhc.gov.cn/yzygj/s7659/201703/d2f580480cef4ab1b976542b550f36cf. shtml.
[20]	Nhan, D.; Lentz, E.J.M.; Steinberg, M.; Bell, C.M.; Morris, A.M. Structure of antimicrobial stewardship programs in leading US hospitals: findings of a nationwide survey. Open Forum Infect. Dis. 2019, 6, ofz104.
[21]	Kallen, M.C.; Ten Oever, J.; Prins, J.M.; Kullberg, B.J.; Schouten, J.A.; Hulscher, M.E.J.L. A survey on antimicrobial stewardship prerequisites, objectives and improvement strategies: systematic development and nationwide assessment in Dutch acute care hospitals. J. Antimicrob. Chemother. 2018, 73, 3496–3504.
[22]	Howard, P.; Pulcini, C.; Levy Hara, G.; West, R.M.; Gould, I.M.; Harbarth, S.; Nathwani, D.; ESCMID Study Group for Antimicrobial Policies (ESGAP), ISC Group on Antimicrobial Stewardship An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J. Antimicrob. Chemother. 2015, 70, 1245–1255.
[23]	Livorsi, D.J.; Heintz, B.; Jacob, J.T.; Krein, S.L.; Morgan, D.J.; Perencevich, E.N. Audit and feedback processes among antimicrobial stewardship programs: a survey of the society for healthcare epidemiology of America research network. Infect. Control. Hosp. Epidemiol. 2016, 37, 704–706.
[24]	Doron, S.; Nadkarni, L.; Lyn Price, L.; Kenneth Lawrence, P.; Davidson, L.E.; Evans, J.; Garber, C.; Snydman, D.R. A nationwide survey of antimicrobial stewardship practices. Clin. Ther. 2013, 35, 758–765.e20.
[25]	Pedersen, C.A.; Schneider, P.J.; Santell, J.P. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing: 2001. Am. J. Health. Syst. Pharm. 2001, 58, 2251–2266.
[26]	Weier, N.M.; Tebano, G.; Thilly, N.; Demoré, B.; Pulcini, C.; Zaidi, S.T.R. Pharmacist participation in antimicrobial stewardship in Australian and French hospitals: a cross-sectional nationwide survey. J. Antimicrob. Chemother. 2018, 73, 804–813.
[27]	MacDougall, C.; Polk, R.E. Antimicrobial stewardship programs in health care systems. Clin. Microbiol. Rev. 2005, 18, 638–656.
[28]	Paskovaty, A.; Pflomm, J.M.; Myke, N.; Seo, S.K. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int. J. Antimicrob. Agents. 2005, 25, 1–10.
[29]	Zhou, J.; Ma, X. A survey on antimicrobial stewardship in 116 tertiary hospitals in China. Clin. Microbiol. Infect. 2019, 25, 759. e9–759.e14.
[30]	Guiding Principles of Clinical Pathway (Polit). This article can be found online at http://www.gov.cn/gzdt/2009-10/16/content_1441548.htm.
[31]	Clinical pathway of diseases (2019). This article can be found online at http://www.nhc.gov.cn/yzygj/s7659/202001/b3c9e097b0c1471a969d7a63be471759.shtml.
[32]	Carratalà, J.; Garcia-Vidal, C.; Ortega, L.; Fernández-Sabé, N.; Clemente, M.; Albero, G.; López, M.; Castellsagué, X.; Dorca, J.; Verdaguer, R.; Martínez-Montauti, J.; Manresa, F.; Gudiol, F. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch. Intern. Med. 2012, 172, 922–928.
[33]	Hauck, L.D.; Adler, L.M.; Mulla, Z.D. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann. Epidemiol. 2004, 14, 669–675.
[34]	Marrie, T.J. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000, 283, 749.
[35]	Newman, R.E.; Hedican, E.B.; Herigon, J.C.; Williams, D.D.; Williams, A.R.; Newland, J.G. Impact of a guideline on management of children hospitalized with community-acquired pneumonia. Pediatrics. 2012, 129, e597–e604.
[36]	Dellit, T.H.; Chan, J.D.; Skerrett, S.J.; Nathens, A.B. Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices. Infect. Control. Hosp. Epidemiol. 2008, 29, 525–533.
[37]	Ibrahim, E.H.; Ward, S.; Sherman, G.; Schaiff, R.; Fraser, V.J.; Kollef, M.H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 2001, 29, 1109–1115.
[38]	Jenkins, T.C.; Knepper, B.C.; Sabel, A.L.; Sarcone, E.E.; Long, J.A.; Haukoos, J.S.; Morgan, S.J.; Biffl, W.L.; Steele, A.W.; Price, C.S.; Mehler, P.S.; Burman, W.J. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern. Med. 2011, 171, 1072–1079.
[39]	Pollack, L.A.; van Santen, K.L.; Weiner, L.M.; Dudeck, M.A.; Edwards, J.R.; Srinivasan, A. Antibiotic stewardship programs in US acute care hospitals: findings from the 2014 national healthcare safety network annual hospital survey. Clin. Infect. Dis. 2016, 63, 443–449.
[40]	Vlahović-Palčevski, V.; Dumpis, U.; Mitt, P.; Gulbinovič, J.; Struwe, J.; Palčevski, G.; Štimac, D.; Lagergren, Å.; Bergman, U. Benchmarking antimicrobial drug use at university hospitals in five European countries. Clin. Microbiol. Infect. 2007, 13, 277–283.
[41]	Polk, R.E.; Fox, C.; Mahoney, A.; Letcavage, J.; MacDougall, C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin. Infect. Dis. 2007, 44, 664–670.
[42]	Elseviers, M.; Wettermark, B.; Almarsdóttir, A.B.; Andersen, M.; Benko, R.; Bennie, M.; Eriksson, I.; Godman, B.; Krska, J.; Poluzzi, E.; Taxis, K.; Vlahović-Palčevski, V.; Stichele, R.V. Drug utilization research [M]. Chichester, UK: John Wiley & Sons, Ltd, 2016.

2018年中国三级医院抗菌药物管理: 全国性横断面网络调查研究

Antimicrobial stewardship program in China’s tertiary hospitals in 2018: a nationwide cross-sectional online survey

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杜浩鑫, 保琦, 李黄倩玉, 张逸晨, 海沙尔江·吾守尔, 史录文, 管晓东. 中国中老年癌症幸存者健康状况分析[J]. 中国药学(英文版), 2023, 32(9): 744-754.
[2]	钱水莲, 徐欢, 刘文夏, 杨照, 江滨. 基于问卷调查的我国家庭储备药现况分析[J]. 中国药学(英文版), 2023, 32(1): 64-67.
[3]	北京大学药学院. 北京大学药学院李中军、董甦伟获中国化学会糖化学奖[J]. 中国药学(英文版), 2021, 30(5): 446-446.
[4]	李晓娇, 栾树鑫, 张洪, 万洪泉, 陈红, 刘成娇, 刘畅, 丁艳华. 单剂量长效利培酮注射液在中国精神分裂症患者体内的药代动力学、药效学和安全性研究[J]. 中国药学(英文版), 2021, 30(3): 206-217.
[5]	顾洁, 刘燕莉, 许风国, 张永泽, 邵蓉, 陆涛. 我国药学硕士专业学位教育的发展与挑战[J]. 中国药学(英文版), 2021, 30(1): 69-76.
[6]	北京大学药学院. 2019中国高被引科学家出炉, 药学院四位学者入选[J]. 中国药学(英文版), 2020, 29(5): 374-374.
[7]	聂智峰, 满春霞, 伊欣, 刘伊, 郭志刚, 管晓东, 史录文. 取消药品加成政策对57家县级公立医院医疗服务量的影响[J]. 中国药学(英文版), 2020, 29(3): 220-226.
[8]	王壮飞, 管晓东, 周越, 韩晟, 姚鹏, 史录文. 中国中老年人自我药疗发生率及影响因素研究：基于CHARLS 2011年, 2013年和2015年的面板数据[J]. 中国药学(英文版), 2019, 28(6): 430-438.
[9]	韩江雪, 肖春玲, 甘茂罗, 李兴华, 王颖, 郑佳音, 李东升, 刘琛楠, 关艳, 蒙建州, 黄树超, 刘忆霜. IMB-XH1作为新型新德里金属-β-内酰胺酶-1(NDM-1)抑制剂的研究[J]. 中国药学(英文版), 2019, 28(4): 238-246.
[10]	陈孝, 高翔, 陈杰, Sheryl L Chow, Moses S.S. Chow. 中国临床药学新方向: 采用“形式遵循功能”方式, 提高医疗保健效果[J]. 中国药学(英文版), 2018, 27(5): 352-360.
[11]	林向红, 胡豪, 刘伊, 管晓东, 宋佳芳, 史录文. 中国制药企业研发国际化的影响因素综合研究[J]. 中国药学(英文版), 2018, 27(3): 209-214.
[12]	柳欣. 2017年中国药物化学会中的北医药学人[J]. 中国药学(英文版), 2017, 26(9): 692-696.
[13]	张靖, 范潇予, 靳洪涛, 耿兴超. 中国药品非临床研究质量管理规范发展情况的回顾与展望[J]. 中国药学(英文版), 2017, 26(7): 534-544.
[14]	高宇雄, 丁黎, 梁文忠, 蒋华芳. UPLC-MS/MS同时测定人血浆中的丙酸氟替卡松与沙美特罗的方法学研究[J]. 中国药学(英文版), 2017, 26(4): 271-283.
[15]	《中国药学》(英文版). 《中国药学》(英文版)在“中国高校科技期刊研究会第21次年会”上获得多项奖励[J]. 中国药学(英文版), 2017, 26(11): 850-850.